Absci Corporation (ABSI)
NASDAQ: ABSI · Real-Time Price · USD
10.89
+0.68 (6.66%)
At close: Jun 26, 2026, 4:00 PM EDT
10.98
+0.09 (0.83%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Absci Revenue
Absci had revenue of $215.00K in the quarter ending March 31, 2026, a decrease of -81.76%. This brings the company's revenue in the last twelve months to $1.84M, down -61.87% year-over-year. In the year 2025, Absci had annual revenue of $2.80M, down -38.24%.
Revenue (ttm)
$1.84M
Revenue Growth
-61.87%
P/S Ratio
1,004.78
Revenue / Employee
$13,114
Employees
140
Market Cap
1.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.80M | -1.73M | -38.24% |
| Dec 31, 2024 | 4.53M | -1.18M | -20.71% |
| Dec 31, 2023 | 5.72M | -29.00K | -0.50% |
| Dec 31, 2022 | 5.75M | 965.00K | 20.18% |
| Dec 31, 2021 | 4.78M | 2.00K | 0.04% |
| Dec 31, 2020 | 4.78M | 2.72M | 132.04% |
| Dec 31, 2019 | 2.06M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.71B |
| Sarepta Therapeutics | 2.18B |
| Innoviva | 420.69M |
| UroGen Pharma | 140.49M |
| Zymeworks | 81.26M |
| Septerna | 72.26M |
| Vir Biotechnology | 65.50M |
| Mesoblast | 65.38M |
ABSI News
- 15 hours ago - Healthcare stocks have become a haven for investors ditching tech - Market Watch
- 1 day ago - Absci price target raised to $10 from $4.10 at Morgan Stanley - TheFly
- 1 day ago - Absci price target raised to $16 from $8 at H.C. Wainwright - TheFly
- 2 days ago - Absci prices 13.5M shares at $7.41 in public offering - TheFly
- 2 days ago - Absci reports Phase 1 data from human trial of ABS-201 - TheFly
- 2 days ago - Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors - GlobeNewsWire
- 2 days ago - Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - GlobeNewsWire
- 11 days ago - Absci price target raised to $15 from $10 at Guggenheim - TheFly